Phase I trial of anti-MUC1 monoclonal antibody AR20-5 for advanced solid tumours.
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2010
At a glance
- Drugs Anti-MUC1 monoclonal antibody AR20-5 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 05 Nov 2010 New trial record.